rAAV vector compositions, methods for targeting vascular endothelial cells and use in treatment of type I diabetes
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
May 12, 2020
Grant Date -
Mar 1, 2018
app pub date -
Feb 16, 2016
filing date -
Feb 16, 2015
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated rAAV vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more diseases, disorders, or dysfunctions of the mammalian vascular system, and complications from Type I diabetes. Also disclosed are methods for systemic and tissue-localized delivery of therapeutic rAAV-based gene expression cassettes to vascular endothelial cells, tissues, and organs, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications including the treatment of vasculitis, and complications arising from Type I diabetes, such as macular edema, nephropathy, diabetic retinopathy, and the like.
First Claim
Other Claims data not available
Family
International Classification(s)
- 2016 Application Filing Year
- A61K Class
- 19101 Applications Filed
- 13019 Patents Issued To-Date
- 68.16 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 7 Citation Count
- A61K Class
- 66.68 % this patent is cited more than
- 5 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Nov 12, 2027 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Nov 12, 2031 |
